AEON Biopharma restates 2023 financials; non-cash error adds $348M loss; going concern doubt

AEON Biopharma, Inc.

Board concludes Q3 2023 and FY 2023 financials unreliable due to IPR&D write-off misclassification.
Non-cash correction increases reported loss by $348M; cash balances and operating cash flow unaffected.
Company plans to file restated audited FY 2023 financials and amend Q3 2023 10-Q.
Expects to disclose additional material weakness and substantial doubt about going concern for 12 months.
KPMG notified; error has no impact on prior cash or operating cash flow.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

AEON Biopharma, Inc. reported that prior financial statements should not be relied upon.

Action: non reliance
Auditor: KPMG LLP

Exact text from the filing

The Company's management and the Board have discussed the matters described herein with KPMG LLP, the Company's independent registered public accounting firm. The identified error had no impact on the Company’s cash balances or operating cash flows for the quarter ended September 30, 2023 nor the year ended December 31, 2023.

View on SEC.gov

47 auditor changes filed in the last 30 days. Browse all auditor changes →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-24-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.